Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid, methyl ester
- Correlated keywords
- iNOS COX-2 COX2 apoptosis inflammations cancers signalings antidiabetic activity oxidative stress NF-?B NF?B NF-kappaB NFkappaB NF.kappa.B NFkB NF-.kappa.B NF-kappaB NF-kB C28 C-28 CDDOs nitric oxide Nrf2 antioxidant ARE Keap1 oxidative stress inflammations cancers apoptosis inducers inhibitors inhibits inhibitions iNOS COX-2 COX2 ROS RNS heme oxygenase-1 oxygenase eotaxins eotaxin-1 PPARgamma PPAR.gamma. PPARg PPAR-gamma PPAR-.gamma. PPAR-g PPAR? PPAR-? oleanane triterpenoid cellular nitric oxide INF? INF-? INF-gamma INF-.gamma. INF-g INFg INF.gamma. INFgamma ROS/RNS peroxisome proliferator activated receptor RTA402 RTA-402 NSC713200 NSC-713200 TP155 TP 155 CDDO-Me
- Product Overview:
The synthetic oleanane triterpenoid CDDO (Item No. 81035) is a Nrf2 activator that inhibits proliferation and induces differentiation and apoptosis in various cancer cells. The C-28 methyl ester of CDDO (CDDO methyl ester) blocks the cellular synthesis of inducible nitric oxide synthase (iNOS) and inducible COX-2 in INF-?-activated mouse macrophages with an IC50 value of 0.11 nM.{9897,20969} It induces apoptosis, induces differentiation, and inhibits the inflammatory response in various tumor cells through inhibition of I?B? kinase/NF-?B signaling.{21755,21758} CDDO methyl ester has potent antidiabetic activity, reducing proinflammatory cytokine expression in high fat diet-fed type 2 diabetic mice and in Leprdb/db mice and triggering AMP-activated protein kinase and LKB1 activation in muscle and liver.{21757}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.